Results 241 to 250 of about 655,327 (339)
Does Guideline-Directed Medical Therapy Reduce the Incidence of Ventricular Arrhythmias in Patients With HFrEF? [PDF]
Nomoto Y, Kataoka N, Imamura T.
europepmc +1 more source
Prognostic role of TAPSE to PASP ratio in outpatients with left ventricular systolic dysfunction
Abstract Aims Few data are available regarding the role of tricuspid annulus plane systolic excursion to pulmonary artery systolic pressure (TAPSE/PASP), a measurement of right ventricular to pulmonary artery coupling, in patients with chronic heart failure and left ventricular systolic dysfunction.
Mauro Riccardi +9 more
wiley +1 more source
Abstract Background Obesity is a known risk factor for cardiovascular disease (CVD), yet an ‘obesity paradox’ has been observed in various CVD contexts. The impact of obesity on heart failure (HF) patients treated with a wearable cardioverter‐defibrillator (WCD) remains underexplored.
Mohammad Abumayyaleh +18 more
wiley +1 more source
Incidence and risk factors for perioperative hypotension during noncardiac surgery: A retrospective cohort study. [PDF]
Sun Z, Wang K, Ji P.
europepmc +1 more source
Abstract Large clinical data underscore that heart failure is independently associated to an increased risk of negative cognitive outcome and dementia. Emerging evidence suggests that cerebral hypoperfusion, stemming from reduced cardiac output and vascular pathology, may contribute to the largely overlapping vascular dementia and Alzheimer's disease ...
Mauro Massussi +6 more
wiley +1 more source
Sacubitril/valsartan preserves regional cardiac function following myocardial infarction in rats
Parts of the figure were drawn by using pictures from Servier Medical Art. Servier Medical Art by Servier is licensed under a Creative Commons Attribution 3.0 Unported License (https://creativecommons.org/licenses/by/3.0/). Abstract Aims Sacubitril/valsartan (Sac/Val) is used for treatment of heart failure. The effect of Sac/Val on regional dysfunction
Einar Sjaastad Nordén +16 more
wiley +1 more source
Angiotensin II receptor antagonists for the treatment of heart failure: what is their place after ELITE-II and Val-HeFT? [PDF]
McMurray, John J.V.
core +1 more source
ESC Heart Failure, Volume 12, Issue 2, Page 1514-1522, April 2025.
Takamasa Iwai +4 more
wiley +1 more source

